• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2012 Product Image

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2012

  • Published: August 2012
  • 428 pages
  • Global Markets Direct

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2012', provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) therapeutic pipeline. This report provides information on the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). 'Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability READ MORE >

2
List of Tables 7
List of Figures 11
Introduction 13
REPORT COVERAGE 13
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Overview 14
Therapeutics Development 15
An Overview of Pipeline Products for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) 15
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics under Development by Companies 17
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics under Investigation by Universities/Institutes 25
Late Stage Products 35
Comparative Analysis 35
Mid Clinical Stage Products 36
Comparative Analysis 36
Early Clinical Stage Products 37
Comparative Analysis 37
Discovery and Pre-Clinical Stage Products 38
Comparative Analysis 38
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Products under Development by Companies 39
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Products under Investigation by Universities/Institutes 47
Companies Involved in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Development 78
Bristol-Myers Squibb Company 78
Genzyme Corporation 79
Boehringer Ingelheim GmbH 80
F. Hoffmann-La Roche Ltd. 81
Amgen Inc. 82
Gilead Sciences, Inc. 83
Merck & Co., Inc. 84
Gamida Cell Ltd. 85
Generex Biotechnology Corporation 86
Plexxikon Inc. 87
Bio-Path Holdings, Inc. 88
BioSante Pharmaceuticals, Inc. 89
Millennium Pharmaceuticals, Inc. 90
Novartis AG 91
BioMarin Pharmaceutical Inc. 92
Eisai Co., Ltd. 93
Sunesis Pharmaceuticals, Inc. 94
SuperGen, Inc. 95
Cyclacel Pharmaceuticals Inc. 96
Celgene Corporation 97
Incyte Corporation 98
Merck KGaA 99
Access Pharmaceuticals, Inc. 100
4SC AG 101
EntreMed, Inc. 102
EpiCept Corporation 103
Ariad Pharmaceuticals, Inc. 104
Lorus Therapeutics Inc 105
MethylGene Inc 106
OXiGENE, Inc. 107
Critical Outcome Technologies Inc. 108
CSL Limited 109
Sidney Kimmel Comprehensive Cancer Center 110
VCU Massey Cancer Center 111
Array BioPharma Inc. 112
Choongwae Pharma Corp 113
Synta Pharmaceuticals Corp. 114
BioAlliance Pharma SA 115
Sareum Holdings plc 116
Clavis Pharma ASA 117
Innate Pharma SA 118
SymBio Pharmaceuticals Limited 119
Cellerant Therapeutics, Inc. 120
Oryzon 121
Chroma Therapeutics Ltd. 122
Colby Pharmaceutical Company 123
Ambit Biosciences Corporation 124
Actinium Pharmaceuticals, Inc. 125
BioMAS Ltd. 126
Celator Pharmaceuticals, Inc. 127
Altor BioScience Corporation 128
Ascenta Therapeutics, Inc. 129
TMRC Co., Ltd. 130
Coronado Biosciences, Inc. 131
Agios Pharmaceuticals 132
TetraLogic Pharmaceuticals 133
S-BIO Pte Ltd 134
Deciphera Pharmaceuticals, LLC 135
Stemline Therapeutics, Inc. 136
Proacta, Inc. 137
Cornerstone Pharmaceuticals, Inc. 138
Advenchen Laboratories, LLC 139
Onconova Therapeutics, Inc 140
Syndax Pharmaceuticals, Inc. 141
Fate Therapeutics, Inc. 142
NovaLead Pharma Pvt. Ltd. 143
Esperance Pharmaceuticals, Inc. 144
Mirna Therapeutics, Inc. 145
Trillium Therapeutics Inc. 146
KaloBios Pharmaceuticals, Inc. 147
Aprea AB. 148
Kinex Pharmaceuticals, LLC 149
OncoImmune, Inc. 150
Cylene Pharmaceuticals, Inc. 151
SymbioTec GmbH 152
Targa Therapeutics Corp. 153
Sentinel Oncology Limited 154
BerGenBio AS 155
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Therapeutics Assessment 156
Assessment by Monotherapy Products 156
Assessment by Combination Products 157
Assessment by Route of Administration 158
Assessment by Molecule Type 160
Drug Profiles 163
StemEx - Drug Profile 163
PKC-412 - Drug Profile 165
Clolar - Drug Profile 167
vosaroxin - Drug Profile 169
Dacogen - Drug Profile 171
Ceplene - Drug Profile 173
CYC682 - Drug Profile 175
Elacytarabine - Drug Profile 177
Cytosine Arabinoside + Idarubicin + Etoposide + Stem Cell Transplantation - Drug Profile 179
Mylotarg - Drug Profile 180
Daunorubicin + Cytarabine - Drug Profile 181
Daunorubicin + Cytarabine + Midostaurin - Drug Profile 183
Vosaroxin + Cytarabine - Drug Profile 184
Decitabine - Drug Profile 186
Prograf + Methotrexate - Drug Profile 188
Vidaza + Allogeneic Stem Cell Transplantation - Drug Profile 189
Daunorubicin + Cytarabine + Etoposide + Cyclophosphamide + Busulfan + Interleukin-2 + PBSCT - Drug Profile 191
Tretinoin + Cytarabine + Daunorubicin + Arsenic Trioxide + Gemtuzumab + Methotrexate + Mercaptopurine - Drug Profile 194
Aracytine + Daunorubicin - Drug Profile 196
Proleukin + Maxamine - Drug Profile 197
Cyclophosphamide + Busulfan + Peripheral Blood Stem Cell Transplantation + Tacrolimus + Methotrexate - Drug Profile 199
Clolar + Cytarabine - Drug Profile 201
Busulfan + Fludarabine + Peripheral Blood Stem Cell Transplantation + Tacrolimus + Methotrexate - Drug Profile 203
Asparaginase + Cytarabine + Daunorubicin + Etoposide + Thioguanine - Drug Profile 204
Filgrastim + Sargramostim + Busulfan + Cyclophosphamide + Gemtuzumab Ozogamicin + Stem Cell Transplantation - Drug Profile 206
Tretinoin + Cytarabine + Daunorubicin + Mercaptopurine + Methotrexate - Drug Profile 208
Tretinoin + Cytarabine + Daunorubicin + Mercaptopurine + Methotrexate + Arsenic Trioxide - Drug Profile 210
Trisenox + Cytarabine + Idarubicin + Mercaptopurine + Methotrexate + Mitoxantrone Hydrochloride + Tretinoin - Drug Profile 212
Mylotarg + Stem Cell Transplantation_ - Drug Profile 214
R115777 - Drug Profile 215
Cytarabine + Mitoxantrone + Etoposide - Drug Profile 216
Idarubicin + Cytarabine + Daunorubicin Hydrochloride + Dexamethasone + Etoposide + Thioguanine + Radiation Therapy - Drug Profile 218
Mitoxantrone Hydrochloride + Cytarabine + Daunorubicin Hydrochloride + Dexamethasone + Etoposide + Thioguanine + Radiation Therapy - Drug Profile 220
Cytarabine + Daunorubicin + Stem Cell Transplantation - Drug Profile 222
Cytarabine + Idarubicin + Mitoxantrone + All-Trans-Retinoic Acid + Etoposide - Drug Profile 223
Cytarabine + Daunorubicin + Etoposide + Filgrastim - Drug Profile 225
Fludarabine + Cytarabine + Filgrastim - Drug Profile 227
Busulfan + Cyclophosphamide + Melphalan + Allogeneic Hematopoietic Cell Transplantation - Drug Profile 228
Cyclophosphamide + Cyclosporine + Methotrexate + Stem Cell Transplantation + Radiation Therapy - Drug Profile 229
Busulfan + Radiation Therapy + Stem Cell Transplantation - Drug Profile 231
Cytarabine + Daunorubicin + Mylotarg + Filgrastim + Sargramostim - Drug Profile 233
Filgrastim + Sargramostim + Cytarabine + Daunorubicin Hydrochloride + Gemtuzumab Ozogamicin - Drug Profile 235
Filgrastim + Sargramostim + Cytarabine + Daunorubicin Hydrochloride + Gemtuzumab Ozogamicin - Drug Profile 237
Filgrastim + Sargramostim + Cytarabine + Daunorubicin - Drug Profile 239
Filgrastim + Sargramostim + Cytarabine + Daunorubicin - Drug Profile 241
Busulfan + Cyclophosphamide + Thymoglobulin + Cyclosporin + Methylprednisolone + Umbilical Cord Blood Stem Cell Transplantation - Drug Profile 243
Daunoxome - Drug Profile 245
Cladribine - Drug Profile 246
Fludarabine - Drug Profile 247
Cytarabine + Daunorubicin + Etoposide - Drug Profile 248
Cytarabine + Idarubicin + Etoposide + All-Trans Retinoic Acid+ Pegfilgrastim - Drug Profile 250
Mylotarg + Idarubicin + Etoposide + Cytarabine + ATRA + Pegfilgrastim - Drug Profile 252
Cytarabine + Idarubicin + Etoposide + Pegfilgrastim - Drug Profile 254
Cladribine + Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone - Drug Profile 256
Daunorubicine + Cytarabine - Drug Profile 258
Umbilical Cord Blood Transplantation - Drug Profile 259
Hematopoietic Cell Transplantation + Total Body Irradiation - Drug Profile 261
Fludarabine + Cytarabine + Idarubicin + Mylotarg - Drug Profile 263
Busilvex + Fludarabine - Drug Profile 265
Enocitabine + Daunorubicin + Mercaptopurine + Mitoxantrone + Etoposide + Vindesine + Aclarubicin - Drug Profile 266
Filgrastim + Amsacrine + Cyclophosphamide + Cytarabine + Daunorubicin + Etoposide + Idarubicin + Mitoxantrone + Thioguanine + Tretinoin + Radiation Therapy + Stem Cell Transplantation - Drug Profile 268
Filgrastim + Amsacrine + Cyclophosphamide + Cytarabine + Daunorubicin + Etoposide + Idarubicin + Mitoxantrone + Thioguanine + Tretinoin + Radiation Therapy + Stem Cell Transplantation - Drug Profile 272
Mycophenolate Mofetil + Cyclosporine + Radiation Therapy + Stem Cell Transplantation - Drug Profile 276
Vesanoid (ATRA) - Drug Profile 278
Bortezomib + Cytarabine + Daunorubicin + Etoposide - Drug Profile 279
CYC682 + Decitabine - Drug Profile 281
Alemtuzumab + Arsenic Trioxide + Azacitidine + Busulfan + Clofarabine + Cytarabine + Daunorubicin Hydrochloride + Fludarabine Phosphate + Gemtuzumab Ozogamicin + Melphalan + Tipifarnib + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile 282
Cytarabine+ Idarubicin +Etoposide+ Fludarabine +G-CSF - Drug Profile 285
Cytarabine+ Idarubicin +Etoposide+ All-Trans Retinoic Acid+ Pegfilgrastim - Drug Profile 287
Cytarabine+ Idarubicin All-Trans Retinoic Acid+ Mitoxantrone+ Etoposide - Drug Profile 289
Asparaginase + Cytarabine + Daunorubicin + Etoposide + Mylotarg + Mitoxantrone - Drug Profile 291
Daunorubicin + Cytarabine + Mylotarg - Drug Profile 293
Cytarabine + Thioguanine + Daunorubicin + Cyclophosphamide + G-CSF + Stem Cell Transplantation - Drug Profile 295
Cytarabine + Daunorubicin + Etoposide + Hydroxyurea + Idarubicin + Mitoxantrone + Thioguanine + Tretinoin + Valspodar - Drug Profile 298
Cytarabine + Idarubicin + All-Trans Retinoic Acid + Mitoxantrone + Etoposid - Drug Profile 301
Fludarabine + Cytarabine + DaunoXome + Etoposide + Thioguanine + Cyclophosphamide + Busulfan + Melphalan - Drug Profile 303
Liposomal Daunorubicin + Fludarabine + Ara-C + G-CSF - Drug Profile 306
Cytarabine + Daunorubicin + Dexamethasone + Etoposide + Idarubicin + Mitoxantrone + Thioguanine - Drug Profile 308
Cytarabine + Daunorubicin Hydrochloride + Etoposide - Drug Profile 311
Cytarabine + Daunorubicin Hydrochloride + Midostaurin - Drug Profile 313
Genesense + Cytarabine + Daunorubicin Hydrochloride - Drug Profile 315
Aldesleukin +G-CSF + Cyclophosphamide + Cytarabine + Etoposide + Idarubicin + Melphalan + Peripheral Blood Stem Cell Transplantation + Radiation Therapy - Drug Profile 317
Anthracyclines + Liposomal Daunorubicin + 2-CDA + AI - Drug Profile 320
Anti-Thymocyte globulin + Cyclophosphamide + Cytarabine + Methylprednisolone + Thiotepa + Radiation Therapy + Bone Marrow Transplantation - Drug Profile 322
Daunorubicin + Cytarabine - Drug Profile 325
Idarubicin + Cytarabine - Drug Profile 326
Daunorubicin + Chemotherapy - Drug Profile 327
Idarubicin + Chemotherapy - Drug Profile 328
Cytarabine + Daunorubicin - Drug Profile 329
Cytosine Arabinoside - Drug Profile 330
Decitabine + Clofarabine - Drug Profile 331
Gemtuzumab Ozogamicin - Drug Profile 332
Lomustine + Idarubicin + Cytarabine - Drug Profile 333
ATRA - Drug Profile 335
Busulfan + Fludarabine + Radiation Therapy - Drug Profile 336
Ara-C + Mitoxantrone + Daunorubicin + Thioguanine - Drug Profile 337
Clofarabine + Etoposide + Cyclophosphamide - Drug Profile 339
Cytarabine + Bortezomib + Mitoxantrone - Drug Profile 341
Cytarabine + Daunorubicin + Etoposide + Bortezomib + Mitoxantrone + Asparaginase - Drug Profile 343
Cytarabine + Daunorubicin + Etoposide + Sorafenib + Mitoxantrone - Drug Profile 345
Cytarabine + Daunorubicin + Etoposide + Bortezomib + Fludarabine + Busulfan + Stem Cell Transplantation - Drug Profile 347
Cytarabine + Daunorubicin + Etoposide + Sorafenib + Fludarabine + Busulfan + Stem Cell Transplantation - Drug Profile 349
Cytarabine + Mitoxantrone + Bortezomib + Fludarabine + Busulfan + Stem Cell Transplantation - Drug Profile 351
Sapacitabine - Drug Profile 353
Cytarabine - Drug Profile 354
Ara-C + Vosaroxin - Drug Profile 355
Ara-C + AC220 - Drug Profile 356
Gemtuzumab Ozogamicin + Fludarabine + Cytarabine + Idarubicin - Drug Profile 357
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Drug Profile Updates 359
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Discontinued Products 374
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics - Dormant Products 381
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Product Development Milestones 412
Featured News & Press Releases 412
Appendix 419
Methodology 419
Coverage 419
Secondary Research 419
Primary Research 419
Expert Panel Validation 419
Contact Us 420
Disclaimer 420

List of Tables
Number of Products Under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H2 2012 22
Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Comparative Analysis, H2 2012 23
Number of Products under Development by Companies, H2 2012 25
Number of Products under Development by Companies, H2 2012 (Contd..1) 26
Number of Products under Development by Companies, H2 2012 (Contd..2) 27
Number of Products under Development by Companies, H2 2012 (Contd..3) 28
Number of Products under Development by Companies, H2 2012 (Contd..4) 29
Number of Products under Development by Companies, H2 2012 (Contd..5) 30
Number of Products under Development by Companies, H2 2012 (Contd..6) 31
Number of Products under Investigation by Universities/Institutes, H2 2012 33
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 34
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 35
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 36
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 37
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 38
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 39
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 40
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 41
Comparative Analysis by Late Stage Development, H2 2012 42
Comparative Analysis by Mid Clinical Stage Development, H2 2012 43
Comparative Analysis by Early Clinical Stage Development, H2 2012 44
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 45
Products under Development by Companies, H2 2012 46
Products under Development by Companies, H2 2012 (Contd..1) 47
Products under Development by Companies, H2 2012 (Contd..2) 48
Products under Development by Companies, H2 2012 (Contd..3) 49
Products under Development by Companies, H2 2012 (Contd..4) 50
Products under Development by Companies, H2 2012 (Contd..5) 51
Products under Development by Companies, H2 2012 (Contd..6) 52
Products under Development by Companies, H2 2012 (Contd..7) 53
Products under Investigation by Universities/Institutes, H2 2012 54
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 55
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 56
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 57
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 58
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 59
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 60
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 61
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 62
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 63
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 64
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 65
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 66
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 67
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 68
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 69
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 70
Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 71
Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 72
Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 73
Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 74
Products under Investigation by Universities/Institutes, H2 2012 (Contd..21) 75
Products under Investigation by Universities/Institutes, H2 2012 (Contd..22) 76
Products under Investigation by Universities/Institutes, H2 2012 (Contd..23) 77
Products under Investigation by Universities/Institutes, H2 2012 (Contd..24) 78
Products under Investigation by Universities/Institutes, H2 2012 (Contd..25) 79
Products under Investigation by Universities/Institutes, H2 2012 (Contd..26) 80
Products under Investigation by Universities/Institutes, H2 2012 (Contd..27) 81
Products under Investigation by Universities/Institutes, H2 2012 (Contd..28) 82
Products under Investigation by Universities/Institutes, H2 2012 (Contd..29) 83
Products under Investigation by Universities/Institutes, H2 2012 (Contd..30) 84
Bristol-Myers Squibb Company, H2 2012 85
Genzyme Corporation, H2 2012 86
Boehringer Ingelheim GmbH, H2 2012 87
F. Hoffmann-La Roche Ltd., H2 2012 88
Amgen Inc., H2 2012 89
Gilead Sciences, Inc., H2 2012 90
Merck & Co., Inc., H2 2012 91
Gamida Cell Ltd., H2 2012 92
Generex Biotechnology Corporation, H2 2012 93
Plexxikon Inc., H2 2012 94
Bio-Path Holdings, Inc., H2 2012 95
BioSante Pharmaceuticals, Inc., H2 2012 96
Millennium Pharmaceuticals, Inc., H2 2012 97
Novartis AG, H2 2012 98
BioMarin Pharmaceutical Inc., H2 2012 99
Eisai Co., Ltd., H2 2012 100
Sunesis Pharmaceuticals, Inc., H2 2012 101
SuperGen, Inc., H2 2012 102
Cyclacel Pharmaceuticals Inc., H2 2012 103
Celgene Corporation, H2 2012 104
Incyte Corporation, H2 2012 105
Merck KGaA, H2 2012 106
Access Pharmaceuticals, Inc., H2 2012 107
4SC AG, H2 2012 108
EntreMed, Inc., H2 2012 109
EpiCept Corporation, H2 2012 110
Ariad Pharmaceuticals, Inc., H2 2012 111
Lorus Therapeutics Inc, H2 2012 112
MethylGene Inc, H2 2012 113
OXiGENE, Inc., H2 2012 114
Critical Outcome Technologies Inc., H2 2012 115
CSL Limited, H2 2012 116
Sidney Kimmel Comprehensive Cancer Center, H2 2012 117
VCU Massey Cancer Center, H2 2012 118
Array BioPharma Inc., H2 2012 119
Choongwae Pharma Corp, H2 2012 120
Synta Pharmaceuticals Corp., H2 2012 121
BioAlliance Pharma SA, H2 2012 122
Sareum Holdings plc, H2 2012 123
Clavis Pharma ASA, H2 2012 124
Innate Pharma SA, H2 2012 125
SymBio Pharmaceuticals Limited, H2 2012 126
Cellerant Therapeutics, Inc., H2 2012 127
Oryzon, H2 2012 128
Chroma Therapeutics Ltd., H2 2012 129
Colby Pharmaceutical Company, H2 2012 130
Ambit Biosciences Corporation, H2 2012 131
Actinium Pharmaceuticals, Inc., H2 2012 132
BioMAS Ltd., H2 2012 133
Celator Pharmaceuticals, Inc., H2 2012 134
Altor BioScience Corporation, H2 2012 135
Ascenta Therapeutics, Inc., H2 2012 136
TMRC Co., Ltd., H2 2012 137
Coronado Biosciences, Inc., H2 2012 138
Agios Pharmaceuticals, H2 2012 139
TetraLogic Pharmaceuticals, H2 2012 140
S-BIO Pte Ltd, H2 2012 141
Deciphera Pharmaceuticals, LLC, H2 2012 142
Stemline Therapeutics, Inc., H2 2012 143
Proacta, Inc., H2 2012 144
Cornerstone Pharmaceuticals, Inc., H2 2012 145
Advenchen Laboratories, LLC, H2 2012 146
Onconova Therapeutics, Inc, H2 2012 147
Syndax Pharmaceuticals, Inc., H2 2012 148
Fate Therapeutics, Inc., H2 2012 149
NovaLead Pharma Pvt. Ltd., H2 2012 150
Esperance Pharmaceuticals, Inc., H2 2012 151
Mirna Therapeutics, Inc., H2 2012 152
Trillium Therapeutics Inc., H2 2012 153
KaloBios Pharmaceuticals, Inc., H2 2012 154
Aprea AB., H2 2012 155
Kinex Pharmaceuticals, LLC, H2 2012 156
OncoImmune, Inc., H2 2012 157
Cylene Pharmaceuticals, Inc., H2 2012 158
SymbioTec GmbH, H2 2012 159
Targa Therapeutics Corp., H2 2012 160
Sentinel Oncology Limited, H2 2012 161
BerGenBio AS, H2 2012 162
Assessment by Monotherapy Products, H2 2012 163
Assessment by Combination Products, H2 2012 164
Assessment by Stage and Route of Administration, H2 2012 166
Assessment by Stage and Molecule Type, H2 2012 169
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Drug Profile Updates 366
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Discontinued Products 381
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Discontinued Products (Contd..1) 382
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Discontinued Products (Contd..2) 383
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Discontinued Products (Contd..3) 384
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Discontinued Products (Contd..4) 385
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Discontinued Products (Contd..5) 386
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Discontinued Products (Contd..6) 387
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products 388
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..1) 389
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..2) 391
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..3) 392
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..4) 393
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..5) 394
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..6) 395
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..7) 396
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..8) 397
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..9) 398
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..10) 399
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..11) 400
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..12) 401
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..13) 402
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..14) 403
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..15) 404
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..16) 405
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..17) 406
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..18) 407
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..19) 408
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..20) 409
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..21) 410
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..22) 411
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..23) 412
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..24) 413
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..25) 414
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..26) 415
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..27) 416
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..28) 417
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics – Dormant Products (Contd..29) 418

List of Figures
Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H2 2012 22
Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Comparative Analysis, H2 2012 23
Products under Development by Companies, H2 2012 24
Products under Investigation by Universities/Institutes, H2 2012 32
Late Stage Products, H2 2012 42
Mid Clinical Stage Products, H2 2012 43
Early Clinical Stage Products, H2 2012 44
Discovery and Pre-Clinical Stage Products, H2 2012 45
Assessment by Monotherapy Products, H2 2012 163
Assessment by Combination Products, H2 2012 164
Assessment by Route of Administration, H2 2012 165
Assessment by Stage and Route of Administration, H2 2012 166
Assessment by Molecule Type, H2 2012 167
Assessment by Stage and Molecule Type, H2 2012 168

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos